A randomized crossover comparison of acebutolol and methyldopa in the treatment of mild to moderate essential hypertension

Summary In a randomized crossover comparison between acebutolol and methyldopa for the treatment of mild to moderate essential hypertension in 30 patients, acebutolol, a cardioselective beta-one-adrenergic blocker, at 400 to 800 mg daily was found to be significantly better (p < 0.002) than 500 t...

Ausführliche Beschreibung